Counterflow Centrifuge Device Receives 2017 Good Design Award®

Caladrius Biosciences in collaboration with Invetech have announced that the Counterflow Centrifuge Device (CFC), a closed platform for washing and concentrating cells, was selected as best in category for medical and scientific product design by 2017 Good Design Award®

PCT, prior to sale to Hitachi, was integral to the conception and functionality of the award-winning device. 

Orchard Therapeutics Ltd. Announces a Manufacturing Services Agreement with PCT Cell Therapy Services, LLC

Orchard Therapeutics Limited (“Orchard”), a clinical-stage biotechnology company dedicated to bringing transformative ex-vivo gene therapies to patients with rare diseases of high unmet medical need announces today that it has entered a new clinical manufacturing services agreement with PCT Cell Therapy Services, LLC (“PCT”), a Hitachi Group Company.

PCT to be Hitachi Chemical’s global brand in fast-growing regenerative medicine market


Hitachi Chemical Completes Acquisition of PCT, Expanding Cell Therapy Outsourcing Business

PCT announced today that Hitachi Chemical Co. America, Ltd. (Hitachi Chemical’s consolidated subsidiary) has completed its purchase of the 80.1% remaining membership interest in PCT from Caladrius Biosciences. With this acquisition, PCT becomes an independent business unit focused on cell therapy and regenerative medicine within the life sciences division of Hitachi Chemical.

Executive Interview - PCT: Manufacturing the Future of Cell Therapies


In an interview published in the May 2017 issue of Drug Development & Delivery, PCT President Robert Preti, PhD, discusses PCT’s founding, differentiators, growth, and vision for the future. Following is an excerpt from that interview:

Understanding Today’s CAR-T Cell Therapy Manufacturing Challenges


Cell therapy presents many difficult challenges -- impacting not only the manufacturer, but also the clinician and patient. From product lot failure, which can lead to the patient not receiving treatment, to the product being given to the wrong person; in both cases, a life is at risk.